Q&A

Yes. For many patients, we are able to identify genetic alterations which are associated with sensitivity or resistance to chemotherapy or endocrine therapies. This information is included in our clinical reports.

Liquid biopsies are best suited to monitor a patient’s tumor burden. Certain genetic alterations that are associated with therapy sensitivity and resistance can also be detected, and this information can provide therapeutic guidance for some patients. However, due to the low tumor DNA proportion in the blood, much information about genetic alterations in a patient’s tumor are lost in liquid biopsies compared to tumor samples. The gene number and exon coverage are limited in those assays, and the detection of copy number alterations remains difficult. For an evaluation of therapeutic choices, tumor samples should be used if available.

Traditional cancer treatment does not consider results of comprehensive genetic testing. However, scientific and clinical evidence show that guiding therapeutic choices by genetic testing greatly increases the proportion of patients who benefit from the treatment, leading to improved clinical outcomes. Note: There is substantial evidence that precision medicine is improving clinical outcomes for cancer patients. For example, the University of Texas MD Anderson Cancer Center and the University of California, San Diego published data from clinical studies demonstrating that therapy selection based on the results of genetic testing can improve overall survival. Furthermore, the National Cancer Institute (NCI) and the American Society of Clinical Oncology (ASCO) are currently conducting large precision medicine clinical trials to demonstrate that precision medicine leads to improved clinical outcomes.

We will discuss therapeutic options with treating physicians based on data such as gene mutation frequency, affected cancer signaling pathways and the patient’s cancer type. We also provide information about the results of related clinical trials to help with the evaluation of therapeutic choices.

The test TodsysHealth®+ provides comprehensive testing including more than 400 cancer-related genes and can be used for all solid tumor types. Similarly, the panel TodsysHealth™ can be used to monitor the tumor burden of patients with solid tumors. Some other panels or subpanels, such as TodsysHealth®+, TodsysHealth and cancer type specific TodsysHealth™ subpanels, are designed for patients with certain cancer types.

© 2019 Todsyshealth. All rights reserved.